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Involvement of community pharmacists in the detection and control of hypertension 
improves patient care. However, current European or North-American guidelines do 
not provide specific guidance how to implement collaboration between pharmacists 
and physicians, especially when and how to refer patients with undetected or uncon-
trolled hypertension to a physician. The German Society of Cardiology and the ABDA 
– Federal Union of German Associations of Pharmacists developed and tested refer-
ral recommendations for community pharmacists, embedded in two guideline work-
sheets. The project included a guideline-directed blood pressure (BP) measurement 
and recommendations when patients should be referred to their physician. A “red 
flag” referral within 4 weeks was recommended when SBP was >140 mm Hg or DBP 
>90 mm Hg (for subjects <80 years), and >160 mm Hg or >90 mm Hg (≥80 years) in 
undetected individuals, or >130 mm Hg or >80 mm Hg (<65 years) and >140 mm Hg 
or >80 mm Hg (≥65 years) in treated patients. BP was measured in 187 individuals 
(86 with known hypertension, mean [±SD] age 62 ± 15 years, 64% female, and 101 
without known hypertension, 47 ± 16 years, 75% female) from 17 community phar-
macies. In patients with hypertension, poorly controlled BP was detected in 55% 
(n = 47) and were referred. A total of 16/101 subjects without a history of hyper-
tension were referred to their physician because of uncontrolled BP. Structured BP 
testing in pharmacies identified a significant number of subjects with undetected/
undiagnosed hypertension and patients with poorly controlled BP. Community phar-
macists could play a significant role in collaboration with physicians to improve the 
management of hypertension.
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1  | INTRODUC TION
Arterial hypertension is the most important risk factor for cardio-
vascular diseases worldwide.1 In developed countries, prevalence 
among adults is at least 30%.2-5 Prevalence is age-related to about 
71% of 65 to 79-year-olds being affected.2,4 A high number of hy-
pertensive persons are unaware of their disease.3,4,6 Although hy-
pertension care has improved, the blood pressure (BP) control rates 
in Germany remain unsatisfactorily low with 30% of patients being 
not at target.2 The latest EURO-ASPIRE V study showed that BP re-
mained uncontrolled (<140 mm Hg systolic [SBP] and <90 mm Hg 
diastolic blood pressure [DBP]) in 42% of patients even after a car-
diovascular event.7
Community pharmacies are an accessible and frequent point of 
contact for many people for various health issues. Pharmacies offer 
BP measurement as health service in several countries.8-15 However, 
current guidelines do not provide guidance on this service in col-
laboration with physicians. In particular, when pharmacists should 
refer a patient to a physician for further evaluation has not been de-
fined. This holds true for both undetected/undiagnosed persons and 
hypertensive patients with poorly controlled BP. In order to enable 
community pharmacists to provide recommendations based on the 
measured BP values, and to judge the size of their impact, referral 
recommendations were developed by the German Cardiac Society 
(DGK) and the ABDA – Federal Union of German Associations of 
Pharmacists which were embedded in two guideline worksheets. 
The purpose of this study was to evaluate the implementation of 
these guidelines.
2  | METHODS
Two different guideline worksheets were developed (Figure 1) 
for the target groups “Subjects without known hypertension” 
(Figures S1 and S2) and “Patients with known hypertension” 
(Figures S3 and S4). They were based on a previously designed 
worksheet for community pharmacists with regard to blood glu-
cose measurements.16 We used the current hypertension guide-
line of the European Society of Cardiology (ESC) and the European 
Society of Hypertension (ESH)4 to specify BP threshold values for 
the recommended measures and to agree on further content and 
design.
In short, the current ESC/ESH guideline recommends to base 
the diagnosis of hypertension on repeated office BP measurements 
or out-of-office BP measurement with ambulatory BP monitoring 
(ABPM) and/or home BP monitoring (HBPM).4 According to guide-
line recommendations, the BP in the pharmacy should be taken after 
a 5-minute resting period, with three BP measurements while seated 
with each measurement at intervals of 1 to 2 minutes.4,17 Triple mea-
surement minimizes the impact of interfering factors, such as stress, 
excitement or pain, and natural BP fluctuations. Pauses of at least 
one minute between the individual measurement cycles are neces-
sary to normalize blood circulation in the arm.4,17
According to the ESC/ESH guideline, the diagnosis of hyper-
tension is based on an office-based BP of >140/90 mm Hg4,18 and 
an 24-hour average of >130/80 mm Hg. During the day, BP should 
not exceed 135/85 mm Hg, and at night, values should not exceed 
120/70 mm Hg.4,18 The office BP criteria were the basis for the risk 
categories of the guideline worksheets. The risk categories enable a 
recommendation of the appropriate action based on the measured 
values.
The measured BP values (including pulse rates) and the mean of 
the last two BP measurements should be recorded on the guideline 
worksheet (Figure 1).19 Based on this, the appropriate risk category 
is selected. The guideline worksheets offer three risk categories fol-
lowing a traffic light scheme for interpretation of the calculated mean 
values: red, yellow, and green. For classification, both mean SBP and 
DBP values are considered. Additionally, the categorization is subdi-
vided by patients’ age (<65/≥65 years for patients with hypertension 
and <80/≥80 years for persons with no known hypertension). If the 
SBP or DBP mean value results in different measurements in each 
case, the higher risk category shall be selected. It must be noted that 
the respective BP values and the recommended measures differ on 
both guideline worksheets (Figure 1 and Figures S1-S4).19
For patients with hypertension, the green category corre-
sponds to a well-controlled BP which should be regularly monitored. 
Measured values of the yellow category should be submitted to 
the general practitioner or family physician at the next regular visit. 
Subjects without hypertension should take their BP measurement at 
least every 3 years (green category) or annually (yellow category). For 
What is known about this topic?
• There is strong evidence for the efficacy of pharmacist 
care in hypertension.
• There is a lack of guidance on how to implement this 
care, especially on how to establish collaboration be-
tween pharmacists and physicians.
• A recommendation when and how to refer patients with 
undetected or uncontrolled hypertension to a physician 
is absent.
What this study adds?
• We developed and tested recommendations for referral, 
embedded in two guideline worksheets for community 
pharmacists in Germany.
• Structured blood pressure testing in community phar-
macies identified a significant number of patients with 
undetected/undiagnosed hypertension and patients 
with poorly controlled blood pressure.
• Community pharmacists could play a significant role in 
collaboration with physicians to improve the manage-
ment of hypertension.
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BP values in the red range, all patients should consult their primary 
care physician for evaluation within the next four weeks (Figure 1). 
BP values higher than 180/110 mm Hg constitute an emergency sit-
uation and require immediate physician follow-up.
As some BP monitoring devices can also detect arrhythmias, 
documentation was also provided on the guideline worksheets 
(Figures S1-S4). If there is evidence of previously unknown arrhyth-
mias, this should be promptly evaluated by a physician, irrespective 
of the measured BP. The same applies to a sustained resting pulse 
rate of >100 beats per minute.
Finally, known cardiovascular risk factors and in case of patients 
with hypertension cardiovascular drugs should be documented 
(Figures S1-S4).
In the development stage, nine community pharmacists from five 
different Federal States received drafts of the guideline worksheets. 
A standardized questionnaire was used to assess understandability 
during a telephone interview. The guideline worksheets were opti-
mized based on the feedback provided.
We intended to test the guideline worksheets in at least 15 
different community pharmacies from different regions, and at 
least 150 patients: 75 patients with known hypertension and 75 
individuals without a history of hypertension. Eligible community 
pharmacies had previous trial experience and were approached 
for participation personally. Community pharmacists were asked 
to participate because they were personally known to members 
of the study team. They were contacted via phone, and in case 
of consent, they received written material for comprehensive in-
formation on the study procedures. To standardize the measur-
ing process, they got the updated standard operating procedure 
“Blood Pressure Measurement in Community Pharmacies.”19 For 
documentation, they received a sufficient number of worksheets 
and documentation forms to answer questions about each mea-
surement. Copies of the filled-in worksheets and documentation 
forms were to be send back at the end of the study. No further 
training was provided.
Participants were asked to measure the BP of five patients with 
previously known hypertension, and of five persons without diag-
nosed hypertension, using the provided BP guideline worksheets 
(Figures S1-S4).19
At baseline, we conducted an online survey to assess the current 
procedure of BP measurement in the participating pharmacies. Thus, 
we asked for the type (upper arm or wrist) and functions (detection 
of arrhythmias) of the BP device used in general, the frequency 
of measurements, the reasons to measure BP, and the procedure 
F I G U R E  1   Traffic light guidelines for referral in community pharmacies. A, Screening for hypertension. B, Patients with hypertension. 
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure
(A)
(B)
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(resting period, repetition of measurement, and documentation of 
results).
According to the standard operating procedure,19 BP shall be 
measured in a quiet and separated area in the pharmacy. Before the 
measurement, the person was instructed to sit calmly for at least five 
minutes. Upper arm monitors with a suitable cuff size were used. 
All measured values, known cardiovascular risk factors, and the risk 
category were recorded on the worksheet (Figures S1-S4). For each 
measurement, feedback on the procedure and feedback received 
by the patients were documented so that the acceptance could be 
assessed.
Additionally, we conducted an online survey at the end of the 
study to better understand the feasibility of the guideline work-
sheets. We asked for the general feasibility, for missing information, 
for future use of the worksheets, and for the possible impact on their 
future BP measurements. They were also encouraged to give further 
considerations on the use of the worksheets.
2.1 | Statistical analysis
Descriptive statistics were used to report patient characteristics. 
Means ± standard deviations (SD) for continuous variables, and fre-
quencies and percentages for categorical variables were presented. 
For non-normal continuous outcomes, medians with interquar-
tile ranges (IQR) were also provided. Microsoft Excel® 2016 was 
used for these analyses. Mean differences were tested with Mann-
Whitney U test. For all nominal values, differences in frequencies 
between groups were tested with Fisher's exact test. Comparison of 
risk categories between groups was analyzed by the chi-square test. 
TA B L E  1   Results of the survey before study participation (at baseline); N = 17
Item Category n (%) Free text answers (examples)
Type of generally used BP device Upper arm 17 (100)
Wrist 0 (0)





Device is able to detect arrhythmias Yes 14 (82)
No 3 (18)
Frequency of BP measurements in 
pharmacy
Daily 2 (12)
>2 times/wk 1 (6)
1-2 times/wk 8 (47)
Once per month 6 (35)
Reasons for measuring BP Patient request 16 (94)
During campaign weeks 8 (47)
Indication identified during 
consultation
12 (71)
Other 4 (24) Within health assessments provided by the 
pharmacy; support of bonus programs of 
health insurers; reference measurements to 
verify functioning of patients’ BP device
Duration of resting period [min], 
median (IQR)
- 5 (2.5-10)




Reasons for repetition Verify first measure to exclude 
technical errors
3 (60)
Verify first measure to exclude 
false measurements
3 (60)
Repetition to calculate mean of 
BP values
2 (40)
Other 1 (20) Following general recommendations
Documentation of results for patient Yes 16 (94)
No 1 (6)
Abbreviations: BP, blood pressure; IQR, interquartile range.
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Statistical analyses were conducted using IBM SPSS® 22. P-values 
<.05 were considered statistically significant.
3  | RESULTS
Of 24 community pharmacies approached, 18 agreed to participate. 
Eventually, 17 pharmacies located in nine different Federal States 
provided a full data set of BP measurements. The median (IQR) num-
ber of filled-in guideline worksheets provided was 10 (9-13), range 
4-20.
According to the baseline survey, all participating pharmacies 
used an upper arm BP monitoring device, and 82% of the devices 
were able to display signs of arrhythmias. One pharmacy used a de-
vice to perform automatic triple measurement. One third took BP 
measurements at least once a month; half of them, 1-2 times/wk. 
The remaining pharmacies responded to take BP measurements 
more frequently (Table 1). One main reason to take the BP measure-
ments was the wish of the patient (94%). Pharmacies offered also BP 
measurement when detecting signs of elevated BP during counsel-
ing (71%) or conducted hypertension awareness weeks (47%).
3.1 | Patient characteristics
Pharmacists recorded measurements from 187 subjects, who were 
predominantly female (70%), mean (±SD) age of 54 ± 17 years. Of 
these, 86 (46%) had known hypertension. In 58% of patients with 
previously known hypertension, the diagnosis had been known for 
more than five years. A total of 92% of the patients with known hy-
pertension stated to be treated with antihypertensive drugs, includ-
ing angiotensin-converting enzyme inhibitors (23%), angiotensin-II 
receptor blockers (51%), beta-blockers (43%), diuretics (17%), or cal-
cium channel blockers (28%). These patients were on average older 
(62 ± 15 vs 47 ± 16 years, P < .001) and had more comorbidities such 
as diabetes (P < .001) or coronary artery disease (P = .006) com-
pared with 101 subjects without a previous history of hypertension 
(Table 2).
3.2 | Blood pressure measurements
Pharmacists took a median of 12 (IQR: 10-15) minutes for collec-
tion of cardiovascular risk factors as well as the subsequent triple BP 
measurement and the assessment of the appropriate action based 
on the measured values (Figure 1). None of the 187 procedures were 
interrupted at patient's request or due to other problems, which 
indicates that a triple measurement is feasible in pharmacies. The 
majority of individuals (80%) rated the duration quite acceptable. 
Underlying cardiovascular risk factors were completed by 89% of 
the individuals independently, 9% completed this part with the help 
of pharmacy staff.
The results of guideline-directed BP measurements in the 86 
patients with hypertension are presented in Table 3 and in the 101 
persons without history of hypertension in Table 4, respectively.
Figure 2 depicts the distribution of red, yellow, and green “flags,” 
and as such, the urgency for physician referral. According to the 
guideline worksheets in patients with hypertension, 47 (55%) were 
referred to see their primary care physician within 4 weeks (“red 
flag”) because uncontrolled BP was detected.
Sixteen undiagnosed persons (16%) were referred to see their 
physician within 4 weeks (“red flag”) because of SBP >140 mm Hg 
or DBP >90 mm Hg if <80 years old, and SBP >160 mm Hg or DBP 
>90 mm Hg if 80 years or older (Figure 2). When any patients were 
referred, patients were given the worksheet to show their physician.
Pharmacies found no cases of hypertensive emergency. In four 
patients with hypertension (5%), evidence of previously unknown ar-
rhythmias was documented and these patients were referred. There 
were no documented signs of arrhythmias in the group without his-
tory of hypertension.
3.3 | Final survey
The community pharmacists provided individual feedback at the ter-
mination of the study, which are included in the further improvement 
of the guideline worksheets provided in the Figures S1-S4 as well as 
online in fillable PDF forms.19 The survey illustrated that the proce-
dure with the aid of the guideline worksheets exceeds the standard 
offer of a simple BP measurement in a pharmacy. Therefore, some 
pharmacists concluded that this guideline-directed BP algorithm can 
realistically only be offered as a service with appropriate remunera-
tion. Nevertheless, the majority (64% of the respondents) wanted to 
continue using the guideline worksheets (Table 5).
4  | DISCUSSION
Hypertension remains the single most important risk factor for pre-
mature morbidity and mortality worldwide. Yet, control of this risk 
factor has remained elusive.1-7 In response to this, we developed 
guideline worksheets for community pharmacists to screen patients 
with suspected or known hypertension. Our worksheets offer three 
risk categories showing the recommendation of the appropriate 
action and urgency based on the measured BP values. We demon-
strated that guideline-directed BP measurements, documentation, 
and application of referral criteria are feasible in German community 
pharmacies. In addition, implementation of the guideline worksheets 
uncovered 16% of patients with undetected/undiagnosed hyperten-
sion and 55% of hypertensive patients with poorly controlled BP, il-
lustrating the potential public health importance.
Current evidence around the clinical interpretation of commu-
nity pharmacy BP measurement is mixed. A systematic review and 
meta-analysis suggested a threshold of 135/85 mm Hg for definition 
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of hypertension as reasonable, potentially resulting in a higher sen-
sitivity for detecting patients with truly increased BP in pharmacies. 
However, the impact of this threshold on increased rate of referrals 
to primary care physicians should be considered.15 Interestingly, an 
examination on the “New Medicine Service” in England showed that 
a structured involvement of pharmacists with the first prescription 
of an antihypertensive drug did not result in a relevant increase in 
the workload for the prescribing physicians.20
TA B L E  2   Patient characteristics
Total




Number, n (%) 187 (100) 101 (54) 86 (46) -
Age, mean ± SD (y) 54 ± 17 47 ± 16 62 ± 15 <.001 ***
Female sex, n (%) 131 (70) 76 (75) 55 (64) .106 **
Antihypertensive 
pharmacotherapy*, n (%)
ACE inhibitor - - 20 (23) -
Angiotensin receptor 
blocker
- - 44 (51) -
Beta-blocker - - 37 (43) -
Calcium channel blocker - - 24 (28) -
Diuretic - - 15 (17) -
Number of AHT, n (%) No AHT - - 8 (9)
1 - - 25 (29)
2 - - 25 (29)
3 - - 18 (21)
4 - - 3 (3)
Number of AHT not 
specified
- - 7 (8)
Comorbidities*, n (%) Diabetes 21 (11) 2 (2) 19 (22) <.001 **
Coronary artery disease 18 (10) 4 (4) 14 (16) .006 **
Myocardial infarction 3 (2) 1 (1) 2 (2) .595 **
Heart failure 11 (6) 0 (0) 11 (13) <.001 **
Stroke 6 (3) 0 (0) 6 (7) .009 **
CKD 6 (3) 2 (2) 4 (5) .416 **
Family history for cardiovascular 
diseases*, n (%)
104 (56) 44 (44) 60 (70) <.001 **
Smoking*, yes, n (%) 33 (18) 15 (15) 18 (21) .337 **
Abbreviations: ACE, angiotensin-converting enzyme; AHT, antihypertensive medication; CKD, chronic kidney disease; HTN, hypertension.
*As stated by the patient. 
**Mann-Whitney U test. 
***Fisher's exact test. 
TA B L E  3   Results of guideline-directed blood pressure measurements in n = 86 patients with diagnosed hypertension
Blood pressure measurement
SBP [mm Hg], mean ± SD, median 
(IQR)
DBP [mm Hg], mean ± SD, median 
(IQR)
Pulse rate [min−1], 
mean ± SD, median (IQR)
























Abbreviations: DBP, diastolic blood pressure; IQR, interquartile range; SBP, systolic blood pressure.
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The current guidelines of the ESC/ESH discuss screening pro-
grams for detection of hypertension.4 Depending on BP level, rec-
ommendations for the time intervals for repeat examinations were 
provided. With an optimal BP of <120/80 mm Hg, repeat mea-
surements should be taken every 5 years; with normal BP (120-
129/80-84 mm Hg), every 3 years; and with high normal values 
(130-139/85-89 mm Hg), at least annually.4,18 To support this moni-
toring process and to identify persons with critical BP in community 
pharmacies, our guideline worksheets were based on the office BP 
criteria defined by the ESC/ESH. Our worksheets enable a standard-
ized procedure to handle the results of the measurement based on 
evidence, thus supporting adequate patient care.
At present, hypertension is mainly detected through either op-
portunistic or routine systematic screening by primary care phy-
sicians. However, both methods exclude individuals who do not 
routinely see a physician, or those in whom routine screening is not 
practiced by the physician.21 BP screening in community pharma-
cies takes advantage of the fact that community pharmacists are the 
most accessible primary care provider. It has also been shown that 
24-hour ABPM is feasible in community pharmacies.22,23
Patients are supportive of screening by their pharmacist, im-
proving awareness on their BP status,24-26 and if referred, a median 
of 44% received a new hypertension diagnosis or antihypertensive 
medication.21
In a commentary to the 2017 American College of Cardiology/
American Heart Association hypertension guideline, Dixon 
et al highlighted the opportunity for community pharmacies to 
“serve as a central hub in local communities for BP screening and 
overall cardiovascular health awareness.” We agree that face-to-
face consultations with a community pharmacist should replace 
BP kiosks for screening and monitoring purposes.9 Some studies 
show, however, that quality enhancements in community pharma-
cies need to be implemented.27 Nevertheless, broad implemen-
tation of screening and monitoring protocols at every pharmacy 
could significantly abate the harm of undiagnosed and uncontrolled 
hypertension.9
Together with the standard operating procedures for BP mea-
surement in community pharmacies,19 the guideline worksheets 
presented may help implementing standardized high-quality hyper-
tension screening in community pharmacies to take advantage of 
this underutilized public health resource.
There are numerous randomized controlled trials of pharma-
cist-led and interdisciplinary interventions investigating the impact 
on BP reduction, BP control rates, and reduced cardiovascular 
TA B L E  4   Results of guideline-directed blood pressure measurements in n = 101 subjects with no history of hypertension
Blood pressure measurement
SBP [mm Hg], mean ± SD, median 
(IQR)
DBP [mm Hg], mean ± SD, median 
(IQR)
Pulse rate [min−1], 
mean ± SD, median (IQR)
























Abbreviations: DBP, diastolic blood pressure; IQR, interquartile range; SBP, systolic blood pressure.
F I G U R E  2   Urgency of referral 
according to guideline-directed blood 
pressure measurements (Figure 1) in 101 
subjects without and 86 patients with 
known hypertension (comparison of risk 
categories between groups P < .001). 
Abbreviation: HTN, hypertension
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risk10,12,13,24,28-33 as well as several systematic reviews and me-
ta-analyses published.34-37 These data indicate that compared with 
usual BP management, interventions by pharmacists working in 
community pharmacies were associated with clinically important 
improvement in BP control, whether or not hypertension was associ-
ated with cardiovascular comorbidities. In comparison with patients 
receiving usual care, both SBP and DBP were more decreased and 
medication adherence improved as did control of other cardiovas-
cular risk factors.10,12,13,33-39 This evidence has led to recommend 
pharmacy-based management of hypertension by some guidelines 
and position papers.8,9,40-42
In developed countries, nearly 1 in 3 adults have hypertension 
and another 1 in 5 are undiagnosed.2-5,15 In Germany, approximately 
13% of women and 18% of men aged 18 to 79 years have uncon-
trolled high BP (≥140/90 mm Hg)5 and, between 2008 and 2011, BP 
among hypertensive patients was controlled in only 51.2% (women 
57.5%, men 45.4%).2,5 This translates into approximately 4 million 
adults with unknown hypertension and nearly 10 million hyperten-
sive patients with uncontrolled BP in Germany. In Europe, more than 
20 million41 and in Germany more than 3 million people43 visit a 
pharmacy every day. BP checks delivered in community pharmacies 
can be more convenient, as patients see their pharmacist more fre-
quently than they see their physician and without the need for ap-
pointments. This also allows pharmacists to be proactive in screening 
and monitoring, as asymptomatic patients often do not seek care or 
advice. Community pharmacists have the opportunity to collaborate 
with patients and physicians in the screening and management of 
hypertension.5,8,9,24,26,41,44
4.1 | Limitations
This study tested the feasibility and implementation of measuring 
guideline-directed BP in a selected sample of community pharma-
cies and in a relatively small number of subjects. This sets the stage 
for a more widespread implementation of the guideline worksheets. 
Further, it is likely that there was volunteer bias in the pharmacies 
who participated. Nevertheless, the high number of hypertensive 
patients with poorly controlled BP suggests a clinically important 
impact.
Because of the sample size of pharmacies and subjects, we can-
not give any recommendations on an adequate reimbursement for 
the use of the screening process using the worksheets. The study 
does also not allow interpretations on further interventions regard-
ing BP control, such as adjusting medical regimens, as we did not 
perform medication reviews or assessments of adherence to find 
reasons for the poor BP control in 55% of the hypertensive patients. 
Finally, we did not perform a follow-up to assess whether the identi-
fied persons actually went to see a physician.
5  | CONCLUSION
The development and implementation of a hypertension screening 
and referral guideline were both feasible and identified large num-
bers of patients with suboptimal blood pressure treatment. This pro-
vides vast opportunities to improve hypertension management with 
a likely significant impact on public health. The guideline worksheets 
Item Category n (%)
Free text answers 
(examples)




Important information missing Yes 3 (21) Space for comprehensive 
medication list; space to 
record current symptoms
No 11 (79)
Estimated frequency of using 




 Never  0 (0)  
Impact of using worksheets in 
the pharmacy
Yes 8 (57) Facilitated communication 
with patient and physician; 
performance of repeated 
measurements and 
sufficient resting period; 
better insight into BP 
measurement procedure
No 6 (43)
Further considerations - - Providing service of high 
quality and thus necessary 
time requirement should 
be remunerated
Abbreviation: BP, blood pressure.
TA B L E  5   Results of the survey after 
study participation; N = 14
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now need to be implemented on a larger scale to more fully assess 
their impact. Indeed, a widespread implementation could bring up to 
52 000 community pharmacists in Germany43 alone to help manage 
this important public health issue.
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